In accordance with Biovitrum stock option program 2006:3 TO4
2006/2008, 30 642 new shares have been issued at the price SEK 59.00
per share, resulting in Biovitrum being provided funds of a total of
SEK 1 807 878.00.
After the share issue the outstanding number of shares in Biovitrum
is 46 046 266.
For more information please contact:
Biovitrum
Göran Arvidson, CFO
Phone: +46 8 697 23 68
Erik Kinnman, VP Investor Relations
Phone: +46 8 697 21 50
erik.kinnman@biovitrum.com
About Biovitrum
Biovitrum is a pharmaceutical company with operations in Sweden and
in the UK. The company markets a range of specialist pharmaceuticals.
Using its expertise and experience Biovitrum takes scientific
innovation all the way to the market and to specialist indication
patients with significant medical need. Research expertise and
capabilities include development and production of biotechnology
therapeutics, as well as small molecule discovery and development.
With revenues of approximately SEK 1.3 billion and around 500
employees, Biovitrum is a significant international specialty
pharmaceutical player. Biovitrum's share is listed on the OMX Nordic
Exchange in Stockholm. For more information go to www.biovitrum.com
Biovitrum AB (publ) may be required to disclose the information
provided herein pursuant to the Swedish Securities Markets Act. The
information was provided for public release on December 19, 2008 at
14:00 a.m. CET.
